Pfizer (PFE) announced Phase 2B trial of danuglipron showed statistically significant reductions from baseline in body weight for all doses
- S&P, Nasdaq end at records as inflation data supports rate cut view
- Salesforce rolls out first-ever dividend as Q4 results, guidance beat estimates
- Equities gain on in-line US inflation, Treasury yields dip
- Snowflake Q4 results top estimates; CEO retires
- SEC investigating whether OpenAI misled investors in Altman saga- WSJ
Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.
Twice-daily dosing of danuglipron showed statistically significant reductions from baseline in body weight for all doses, with mean reductions ranging from -6.9% to -11.7%, compared to +1.4% for placebo at 32 weeks, and -4.8% to -9.4%, compared to +0.17% for placebo at 26 weeks. Placebo-adjusted reductions in mean body weight ranged from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks. Depending on titration schedule, participants were at target dose levels for 6 to 24 weeks.
While the most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates were observed (up to 73% nausea; up to 47% vomiting; up to 25% diarrhea). High discontinuation rates, greater than 50%, were seen across all doses compared to approximately 40% with placebo. No new safety signals were reported and treatment with danuglipron was not associated with increased incidence of liver enzyme elevation compared to placebo. Data from this study will be presented at a future scientific conference or published in a peer-reviewed journal.
“We believe an improved once-daily formulation of danuglipron could play an important role in the obesity treatment paradigm, and we will focus our efforts on gathering the data to understand its potential profile,” said Mikael Dolsten, MD., PhD., Chief Scientific Officer & President, Pfizer Research and Development. “Results from ongoing and future studies of the once-daily danuglipron modified release formulation will inform a potential path forward with an aim to improve the tolerability profile and optimize both study design and execution.”
Future development of danuglipron will be focused on a once-daily formulation, with pharmacokinetic data anticipated in the first half of 2024.
Results previously published in the Journal of the American Medical Association Network Open from the Phase 2 study (NCT03985293) of danuglipron in type 2 diabetes showed dose-dependent placebo-adjusted reductions in HbA1c of up to -1.16%; fasting plasma glucose of -33.24 mg/dL; and body weight of -4.17 kg over 16 weeks. Additionally, the Phase 2a study (NCT04617275) of danuglipron in patients with type 2 diabetes who are treated with metformin and in non-diabetic adults with obesity showed robust declines in HbA1c, fasting plasma glucose (FPG) and body weight. In both populations, danuglipron demonstrated a safety and tolerability profile consistent with the mechanism of action.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer (PFE) Reports Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO
- Zscaler (ZS) beats Q2 expectations on top and bottom lines, hikes full-year outlook
- New York Community Bancorp (NYCB) management identified material weaknesses in internal controls related to internal loan review
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News
Related EntitiesTwitter, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!